Page 91 - 16Neonatal Jaundice_compressed
P. 91

Neonatal jaundice





                         phototherapy was 1 in 1827, and it declined  to  1 in 11 995  during 2001–2003. A  similar
                         reduction in readmission rates for intensive  phototherapy was reported:  from 14 per 1000
                         babies discharged in 1994 to 5.5 per 1000 in 2001–2003. No babies developed serum bilirubin
                         levels  ≥ 513 micromol/litre  during the study period,  while the frequency of reported serum
                         bilirubin levels ≥ 427 micromol/litre was 1 in 15 000 compared with the reported incidence of
                                                 9
                         1 in 625 in previous studies.  [EL III]
                                                                   48
                         Another historical cohort study from the  USA   evaluated the  effectiveness of  a bilirubin
                         screening  programme  in  a private  healthcare  organisation  involving 18 hospitals. The
                         programme, started in December 2002, involved measurement of bilirubin in every newborn
                         baby, either on recognition of jaundice or before discharge from hospital. Two hospitals used
                         BiliChek to measure transcutaneous bilirubin levels while others used serum bilirubin; the
                         bilirubin measurements  were plotted on the hour-specific nomogram.  Any bilirubin level
                         ≥ 40th  centile was  notified  to  the relevant  healthcare  provider and  the  baby  managed
                         according to his/her discretion. All babies born at gestational age ≥ 35 weeks were enrolled in
                         the study. Those born after the initiation  of the  programme (1 January 2003 to 31 December
                         2004)  formed  the  cohort  group  (n = 52 483),  while  those  born  before  the  programme  started
                         (1 March 2001 to 31 December 2002) formed the comparison group (n = 48 798). Other details
                         of the two groups  were not given and no comparison was made between their baseline
                         characteristics.

                         Compliance with the programme was good – within 2 months of starting it, more than 99% of
                         the babies had at least one pre-discharge bilirubin level measured. After the first 3 months of the
                         study, the percentiles of the hour-specific nomogram  were  modified since a large number of
                         babies were reported to have bilirubin measurements in the high or intermediate-high zones.
                         A significant decline in the incidence of hyperbilirubinaemia was reported after implementation
                         of the  screening  programme. The proportion of babies  with  serum bilirubin levels
                         ≥ 342 micromol/litre  declined  from  1  in  77  to  1  in  142  (P < 0.0001),  while  the  proportion
                         with serum bilirubin levels  ≥ 427 micromol/litre) declined from 1 in 1522 to 1 in 4037
                         (P < 0.005). The incidence of hospital readmission for hyperbilirubinaemia also fell
                         significantly, from 5.5 per 1000  before the  programme  to 4.3 per  1000  babies after its
                         introduction (P < 0.005). The authors concluded that a universal screening programme coupled
                         with evaluation of bilirubin using a percentile-based nomogram can lead to significant reduction
                         in the incidence of hyperbilirubinaemia and hospital readmissions for phototherapy. [EL II]

                         Evidence summary
                         There is no good-quality prospective comparative study assessing the impact of universal pre-
                         discharge bilirubin testing. Results from two studies with EL III  and EL II  suggest that the
                         introduction of universal bilirubin screening is followed by reduction in the number of hospital
                         readmissions for phototherapy. The non-comparative observational study also found a reduction
                         in  the  incidence  of  intensive  phototherapy  and  exchange  transfusion,  while  the  retrospective
                         study reported a decrease in the frequency  of reported  serum  bilirubin levels
                         ≥ 342 micromol/litre.

                         GDG translation from evidence
                         Low-quality evidence suggests that universal pre-discharge bilirubin testing may reduce the
                         need for intensive phototherapy and  exchange  transfusions, and the readmission rate for
                         significant hyperbilirubinaemia. These studies did not report on bilirubin encephalopathy and
                         stated that there were no  recorded cases of kernicterus. However,  the lack  of high-quality
                         evidence to show that universal pre-discharge bilirubin measurement reduces the frequency of
                         hospital readmission, exchange transfusions and bilirubin encephalopathy means that it is not
                         possible to make a recommendation on the role of universal pre-discharge bilirubin testing in
                         the UK but a research recommendation has been made on this topic.








              62
   86   87   88   89   90   91   92   93   94   95   96